Balancing act

Newly marketed drugs for cystic fibrosis and much of the CF pipeline focus on correcting the mechanisms responsible for aberrant mucus buildup in the airways, but mucus is only half the problem. Laurent Pharmaceuticals Inc. hopes to tackle the other half of the problem with LAU-7b, an oral formulation of fenretinide that could correct the inflammatory imbalance in CF patients.

The company believes the compound could reduce lung deterioration over time, when given on top of SOC...